Brokerage : DS Investment & Securities
Analyst : Minjeong Kim
Investment Rating : BUY
Target Price : KRW 2,100,000
Core Momentum : Full utilization across Plants 1–4 combined with H2 revenue contributions from the 180k-liter Plant 5, the consolidation of the US GSK facility, and the planned groundbreaking of Plant 6 will drive structural operating profit expansion.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY / Target Price KRW 2,100,000 (Upside potential of 34.5% based on the April 22, 2026 closing price of KRW 1,561,000)
- Market Data: Market Cap (Common) KRW 72.26 Trillion / Shares Outstanding 46,291,000 / Foreign Ownership 0.0% / Major Shareholders: Samsung C&T and 6 affiliates 74.3%, National Pension Service and 1 affiliate 6.7%
- Annual Financial Forecast (Consolidated Estimates):
- 2026F: Revenue KRW 5.38 Trillion, Operating Profit KRW 2.68 Trillion, OPM 49.7%, Pre-tax Profit KRW 2.81 Trillion, Net Profit (Controlling) KRW 2.12 Trillion, EPS KRW 29,799, PER 52.4x, PBR 8.5x, ROE 17.7%, EV/EBITDA 22.4x
- Standalone Estimates (2026F): Revenue ~KRW 5.38 Trillion (+18.2% YoY), Operating Profit ~KRW 2.68 Trillion (+28.2% YoY), OPM 45.8%
🚀 2. [Market Opportunities & Business Outlook]
- Q1 2026 Earnings Performance:
- Consolidated revenue posted approximately KRW 1.26 Trillion (+25.8% YoY) and operating profit reached KRW 580.8 Billion (+35.1% YoY, OPM 46.2%), meeting consensus estimates (Revenue KRW 1.28 Trillion, OP KRW 590.2 Billion).
- Solid performance was supported by 100% full capacity utilization across Plants 1 through 4, alongside the recognition of delayed Q4 revenues in Q1.
- Capacity Expansion & Global Footprint Integration:
- The 180,000-liter Plant 5 is scheduled to generate direct top-line contribution starting in H2 2026, with structural operating profit acceleration expected from 2027 as operations scale up fully.
- Acquisition of GSK’s US manufacturing site was finalized at approximately USD 353 Million (USD 280 Million plant purchase + USD 73 Million inventory/spare parts), with top-line recognition commencing in Q2. The 60,000-liter facility has secured orders for ~50% of its capacity, with potential upside as additional contracts materialize.
- Facility Roadmap & Risk Management:
- The company applied for Plant 6 construction permits with the Incheon Free Economic Zone Authority on April 11, reviewing construction start dates targeting completion by 2027.
- Resolution of US tariff uncertainties via local manufacturing acquisition enables aggressive domestic facility expansion.
- Near-term concerns regarding labor friction causing production halts are deemed excessive given management’s commitment to maintaining uninterrupted operations for essential manufacturing processes.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics as a leading global CDMO capable of sustaining high structural profit growth by successfully layering an 180k-liter new facility and a US manufacturing footprint onto its fully utilized legacy infrastructure. The core perspective places strategic significance on mitigating trade policy risks through US asset integration and executing the Plant 6 capacity roadmap, rather than near-term market sentiment surrounding labor negotiations.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the consolidation of the US plant’s revenues starting in Q2, the timeline of initial commercial revenue recognition from Plant 5 in H2, and the formal groundbreaking of Plant 6 within the year. These milestones can be verified through upcoming quarterly earnings releases, official company IR materials, regulatory filings on DART/KRX, and periodic disclosures.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)